http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Convincing Factors in Choosing in e-book and Paper book
김미희(Mihee Kim),정수빈(Subin Jeong),신동희(Donghee Shin),김나혜(Nahye Kim) 한국HCI학회 2012 한국HCI학회 학술대회 Vol.2012 No.1
The issue that of whether e-books would replace printed books have been controversial and the difference between e-book and printed book is still being researched by researchers. Many studies on e-book and printed book have analyzed their advantages and disadvantages, and also suggested ideas to improve the usage of e-book. In the experiment, 18 participants were recruited and exposed to the three different types of media (iPad, Galaxy Tab, and print book). The usability and performance of each media were measured by questionnaires along with the intention of buying one of the media from the experiment. The results imply that the higher familiarity of media is, the more convincing to participants in buying a certain media among other types of media.
신석호(Seok Ho Shin),박민호(Min Ho Park),변진주(Jin Ju Byeon),이병일(Byeong ill Lee),박유리(Yuri Park),최장미(Jangmi Choi),김나혜(Nahye Kim),신영근(Young Geun Shin) 대한약학회 2018 약학회지 Vol.62 No.3
The antibody-drug conjugate (ADC) is one of the most rapidly growing next generation antibody therapies used in oncology, autoimmunity and chronic inflammatory diseases. ADC is consisted of monoclonal antibody conjugated via chemical linker with highly cytotoxic small molecules, called payloads. Due to the rising prevalence of cancer and population aging, there is a consistent unmet needs on novel therapeutics for patients where the traditional antibody therapy does not work. With the successful market settlement of FDA-approved Adcetris?? and Kadcyla??, global pharmaceutical companies have put their resources for development of this innovative drug class. There are still some drawbacks in this class of drug including linker stability and heterogenous drug antibody ratio (DAR) profile. However new platform technologies are making progress to overcome these problems and further investment will drive growth in the next generation antibody therapies market. In this manuscript, we review the market drivers and restraints and introduce four approved ADCs. We then mainly discuss the important aspects considered while developing ADCs (cytotoxic drug, linker, DAR) and ADC platforms widely used in the industries.